
Title:
Hydrocodone
Text:
Opioid drug used in pain relief
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}Not to be confused with Dihydrocodeine.


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}HydrocodoneClinical dataTrade namesHysingla ER, Zohydro EROther namesDihydrocodeinone, hydrocodone bitartrateAHFS/Drugs.comMonographMedlinePlusa601006License data
US DailyMed: Hydrocodone
DependenceliabilityHigh[1]Routes ofadministrationClinical: by mouth[2]Others: intranasal, rectalATC codeR05DA03 (WHO) Legal statusLegal status
AU: S8 (Controlled drug) 
CA: Schedule I 
DE: Anlage III (Special prescription form required) 
UK: Class A 
US: Schedule II 
Pharmacokinetic dataBioavailabilityBy mouth: 70%[3]Protein bindingLow[3][4]MetabolismLiver: CYP3A4 (major), CYP2D6 (minor)[5]Metabolites• Norhydrocodone[5]• Hydromorphone[5]• Others[5]Onset of action10–20 minutes[2]Elimination half-lifeAverage: 3.8 hours[6]Range: 3.3–4.4 hours[2]Duration of action4–8 hours[2]ExcretionUrine[7][8]Identifiers
IUPAC name
4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one
CAS Number125-29-1 YPubChem CID5284569IUPHAR/BPS7081DrugBankDB00956 YChemSpider4447623 YUNII6YKS4Y3WQ7KEGGD08045 YChEBICHEBI:5779 YChEMBLChEMBL1457 YCompTox Dashboard (EPA)DTXSID8023131 ECHA InfoCard100.004.304 Chemical and physical dataFormulaC18H21NO3Molar mass299.370 g·mol−13D model (JSmol)Interactive image
SMILES
O=C4[C@@H]5Oc1c2c(ccc1OC)C[C@H]3N(CC[C@]25[C@H]3CC4)C

InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1 YKey:LLPOLZWFYMWNKH-CMKMFDCUSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Hydrocodone is an opioid used to treat pain and as a cough suppressant.[9] It is taken by mouth.[9] Typically it is dispensed as the combinations acetaminophen/hydrocodone or ibuprofen/hydrocodone, for pain severe enough to require an opioid[10][11] and in combination with homatropine methylbromide to relieve cough.[9] It is also available by itself in a long acting form under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration.[9][12] Hydrocodone is a controlled drug, in the United States a Schedule II Controlled Substance.
Common side effects include dizziness, sleepiness, nausea, and constipation.[9] Serious side effects may include abuse,[clarification needed] low blood pressure, seizures, QT prolongation, respiratory depression, and serotonin syndrome.[9] Rapidly decreasing the dose may result in opioid withdrawal.[9] Use during pregnancy or breastfeeding is generally not recommended.[13] Hydrocodone is believed to work by activating opioid receptors, mainly in the brain and spinal cord.[9] Hydrocodone 10 mg is equivalent to about 10 mg of morphine by mouth.[14]
Hydrocodone was patented in 1923, while the long-acting formulation was approved for medical use in the United States in 2013.[9][15]  It is most commonly prescribed in the United States, which consumed 99% of the worldwide supply as of 2010.[16] In 2017, it was the 118th most commonly prescribed medication in the United States, with more than six million prescriptions.[17][18] Hydrocodone is a semisynthetic opioid, converted from codeine[19][20] or less often from thebaine.[21] Production using genetically engineered yeasts have been developed but are not used commercially.[22][23][24] 

.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}Contents

1 Medical uses

1.1 Available forms


2 Side effects
3 Interactions
4 Pharmacology

4.1 Pharmacodynamics
4.2 Pharmacokinetics

4.2.1 Absorption
4.2.2 Distribution
4.2.3 Metabolism
4.2.4 Elimination




5 Chemistry

5.1 Detection in body fluids
5.2 Synthesis
5.3 Structure


6 History
7 Society and culture

7.1 Formulations

7.1.1 Combination products


7.2 Legal status

7.2.1 United States




8 References
9 External links



Medical uses[edit]
Hydrocodone is used to treat moderate to severe pain. In liquid formulations, it is used to treat cough.[9] In one study comparing the potency of hydrocodone to that of oxycodone, it was found that it took 50% more hydrocodone to achieve the same degree of miosis (pupillary contraction).[25] The investigators interpreted this to mean that oxycodone is about 50% more potent than hydrocodone.
However, in a study of emergency department patients with fractures, it was found that an equal amount of either drug provided about the same degree of pain relief, indicating that there is little practical difference between them when used for that purpose.[26] Some references state that the analgesic action of hydrocodone begins in 20–30 minutes and lasts about 4–8 hours.[27] The manufacturer's information says onset of action is about 10–30 minutes and duration is about 4–6 hours.[28] Recommended dosing interval is 4–6 hours.

Available forms[edit]
See also: Hydrocodone/paracetamol, Hydrocodone/ibuprofen, and Hydrocodone/aspirin
Hydrocodone is available in a variety of formulations for oral administration:[29][30][31]

The original oral form of hydrocodone alone, Dicodid, as immediate-release 5 and 10 mg tablets is available for prescription in Continental Europe per national drug control and prescription laws and Title 76 of the Schengen Treaty, but dihydrocodeine has been more widely used for the same indications since the beginning in the early 1920s, with hydrocodone being regulated the same way as morphine in the German Betäubungsmittelgesetz, the similarly named law in Switzerland and the Austrian Suchtmittelgesetz, whereas dihydrocodeine is regulated like codeine. For a number of decades, the liquid hydrocodone products available are cough medicines.
Hydrocodone plus homatropine (Hycodan) in the form of small tablets for coughing and especially neuropathic moderate pain (the homatropine, an anticholinergic, is useful in both of those cases and is a deterrent to intentional overdose) was more widely used than Dicodid and was labelled as a cough medicine in the United States whilst Vicodin and similar drugs were the choices for analgesia.
Extended-release hydrocodone in a time-release syrup also containing chlorphenamine/chlorpheniramine is a cough medicine called Tussionex in North America. In Europe, similar time-release syrups containing codeine (numerous), dihydrocodeine (Paracodin Retard Hustensaft), nicocodeine (Tusscodin), thebacon, acetyldihydrocodeine, dionine, and nicodicodeine are used instead.
Immediate-release hydrocodone with paracetamol (acetaminophen) (Vicodin, Lortab, Lorcet, Maxidone, Norco, Zydone)
Immediate-release hydrocodone with ibuprofen (Vicoprofen, Ibudone, Reprexain)
Immediate-release hydrocodone with aspirin (Alor 5/500, Azdone, Damason-P, Lortab ASA, Panasal 5/500)
Controlled-release hydrocodone (Hysingla ER by Purdue Pharma, Zohydro ER)[32]
Hydrocodone is not available in parenteral or any other non-oral forms.[4][2]

Side effects[edit]

Common side effects of hydrocodone are nausea, vomiting, constipation, drowsiness, dizziness, lightheadedness, anxiety, abnormally happy or sad mood, dry throat, difficulty urinating, rash, itching, and contraction of the pupils. Serious side effects include slowed or irregular breathing and chest tightness.[33]
Several cases of progressive bilateral hearing loss unresponsive to steroid therapy have been described as an infrequent adverse reaction to hydrocodone/paracetamol misuse. This adverse effect has been considered by some to be due to the ototoxicity of hydrocodone.[34][35] Other researchers have suggested that paracetamol is the primary agent responsible for the ototoxicity.[36][37]
Hydrocodone is in U.S. Food and Drug Administration (FDA) pregnancy category C. No adequate and well-controlled studies in humans have been conducted. A newborn of a mother taking opioid medications regularly prior to the birth will be physically dependent.[38][39] The baby may also exhibit respiratory depression if the opioid dose was high.[40] An epidemiological study indicated that opioid treatment during early pregnancy results in increased risk of various birth defects.[41]
Symptoms of hydrocodone overdose include narrowed or widened pupils; slow, shallow, or stopped breathing; slowed or stopped heartbeat; cold, clammy, or blue skin; excessive sleepiness; loss of consciousness; seizures; or death.[33]
Hydrocodone can be habit forming, causing physical and psychological dependence. Its abuse liability is similar to morphine and less than oxycodone.[42]

Interactions[edit]
Patients consuming alcohol, other opioids, anticholinergic antihistamines, anti-psychotics, anti-anxiety agents, or other central nervous system (CNS) depressants together with hydrocodone may exhibit an additive CNS depression.[40] Hydrocodone may interact with serotonergic medications.[43]

Pharmacology[edit]
Pharmacodynamics[edit]

Hydrocodone (and metabolite) at opioid receptors


Compound
Affinities (Ki)
Ratio
Ref


MOR
DOR
KOR
MOR:DOR:KOR


Hydrocodone
11.1 nM
962 nM
501 nM
1:87:45
[44]


Hydromorphone
0.47 nM
18.5 nM
24.9 nM
1:39:53
[45]


Equianalgesic doses[46][47][48]


Compound
Route
Dose


Codeine
PO
200 mg


Hydrocodone
PO
20–30 mg


Hydromorphone
PO
7.5 mg


Hydromorphone
IV
1.5 mg


Morphine
PO
30 mg


Morphine
IV
10 mg


Oxycodone
PO
20 mg


Oxycodone
IV
10 mg


Oxymorphone
PO
10 mg


Oxymorphone
IV
1 mg

Hydrocodone is a highly selective full agonist of the μ-opioid receptor (MOR).[27][49][44] This is the main biological target of the endogenous opioid neuropeptide β-endorphin.[50] Hydrocodone has low affinity for the δ-opioid receptor (DOR) and the κ-opioid receptor (KOR), where it is an agonist similarly.[44]
Studies have shown hydrocodone is stronger than codeine but only one-tenth as potent as morphine at binding to receptors and reported to be only 59% as potent as morphine in analgesic properties. However, in tests conducted on rhesus monkeys, the analgesic potency of hydrocodone was actually higher than morphine.[6] Oral hydrocodone has a mean equivalent daily dosage (MEDD) factor of 0.4, meaning that 1 mg of hydrocodone is equivalent to 0.4 mg of intravenous morphine. However, because of morphine's low oral bioavailability, there is a 1:1 correspondence between orally administered morphine and orally administered hydrocodone.[51] The relative milligram strength of hydrocodone to codeine is given as 6 fold, that is 5 mg has the effect of 30 mg of codeine; by way of the Roman numeral VI this is said to have given rise to the trade name Vicodin.[citation needed]

Pharmacokinetics[edit]
Absorption[edit]
Hydrocodone is only pharmaceutically available as an oral medication.[2] It is well-absorbed, but the oral bioavailability of hydrocodone is only approximately 25%.[3][4] The onset of action of hydrocodone via this route is 10 to 20 minutes, with a peak effect (Tmax) occurring at 30 to 60 minutes,[52] and it has a duration of 4 to 8 hours.[2]

Distribution[edit]
The volume of distribution of hydrocodone is 3.3 to 4.7 L/kg.[4] The plasma protein binding of hydrocodone is 20 to 50%.[27]

Metabolism[edit]
In the liver, hydrocodone is transformed into several metabolites, including norhydrocodone, hydromorphone, 6α-hydrocodol (dihydrocodeine), and 6β-hydrocodol.[5] 6α- and 6β-hydromorphol are also formed, and the metabolites of hydrocodone are conjugated (via glucuronidation).[53][54] Hydrocodone has a terminal half-life that averages 3.8 hours (range 3.3–4.4 hours).[6][2] The hepatic cytochrome P450 enzyme CYP2D6 converts hydrocodone into hydromorphone, a more potent opioid (5-fold higher binding affinity to the MOR).[5][55] However, extensive and poor cytochrome 450 CYP2D6 metabolizers had similar physiological and subjective responses to hydrocodone, and CYP2D6 inhibitor quinidine did not change the responses of extensive metabolizers, suggesting that inhibition of CYP2D6 metabolism of hydrocodone has no practical importance.[56][57] Ultra-rapid CYP2D6 metabolizers (1–2% of the population) may have an increased response to hydrocodone; however, hydrocodone metabolism in this population has not been studied.[58]
Norhydrocodone, the major metabolite of hydrocodone, is predominantly formed by CYP3A4-catalyzed oxidation.[5] In contrast to hydromorphone, it is described as inactive.[55] However, norhydrocodone is actually a MOR agonist with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals (likely due to poor blood–brain barrier and thus central nervous system penetration).[59] Inhibition of CYP3A4 in a child who was, in addition, a poor CYP2D6 metabolizer, resulted in a fatal overdose of hydrocodone.[60] Approximately 40% of hydrocodone metabolism is attributed to non-cytochrome P450-catalyzed reactions.[61]

Elimination[edit]
Hydrocodone is excreted in urine, mainly in the form of conjugates.[7][8]

Chemistry[edit]
Detection in body fluids[edit]
Hydrocodone concentrations are measured in blood, plasma, and urine to seek evidence of misuse, to confirm diagnoses of poisoning, and to assist in investigations into deaths. Many commercial opiate screening tests react indiscriminately with hydrocodone, other opiates, and their metabolites, but chromatographic techniques can easily distinguish hydrocodone uniquely. Blood and plasma hydrocodone concentrations typically fall into the 5–30 µg/L range among people taking the drug therapeutically, 100–200 µg/L among recreational users, and 100–1,600 µg/L in cases of acute, fatal overdosage. Co-administration of the drug with food or alcohol can very significantly increase the resulting plasma hydrocodone concentrations that are subsequently achieved.[62][63]

Synthesis[edit]
Hydrocodone is most commonly synthesized from Thebaine, a constituent of opium latex from the dried poppy plant. Once Thebaine is obtained, the reaction undergoes hydrolysis using a palladium catalyst.[64]

Structure[edit]
There are three important structures in hydrocodone: the amine group, which binds to the tertiary nitrogen binding site in the central nervous system's opioid receptor, the hydroxy group that binds to the anionic binding side, and the phenyl group which binds to the phenolic binding site.[65] This triggers a G protein activation and subsequent release of dopamine.[66]

History[edit]
Hydrocodone was first synthesized in Germany in 1920 by Carl Mannich and Helene Löwenheim.[67] It was approved by the Food and Drug Administration on 23 March 1943 for sale in the United States and approved by Health Canada for sale in Canada under the brand name Hycodan.[68][69]
Hydrocodone was first marketed by Knoll as Dicodid, starting in February 1924 in Germany. This name is analogous to other products the company introduced or otherwise marketed: Dilaudid (hydromorphone, 1926), Dinarkon (oxycodone, 1917), Dihydrin (dihydrocodeine, 1911), and Dimorphan (dihydromorphine). Paramorfan is the trade name of dihydromorphine from another manufacturer, as is Paracodin, for dihydrocodeine.[70][71]
The name Dicodid was registered in the United States and appears without a monograph as late as 1978 in the Physicians' Desk Reference; Dicodid may have been marketed to one extent or another in North America in the 1920s and early 1930s. The drug was pure hydrocodone in small 5 and 10 mg tablets, physically similar to the Dilaudid tablets. It is no longer manufactured by Knoll in Germany, nor is a generic available. Hydrocodone was never as common in Europe as it is in North America—dihydrocodeine is used for its spectrum of indications. Germany was the number two consumer of hydrocodone until the manufacture of the drug was discontinued there. Now,[when?] the world outside the United States accounts for less than 1% of annual consumption. It was listed as a Suchtgift under the German Betäubungsmittelgesetz and regulated like morphine. It became available in the Schengen Area of the European Union as of 1 January 2002 under Title 76 of the Schengen Treaty.[citation needed]

Society and culture[edit]
Formulations[edit]
Several common imprints for hydrocodone are M365, M366, M367.[72]

Combination products[edit]
Main articles: Hydrocodone/paracetamol and Hydrocodone/ibuprofen
  Hydrocodone and paracetamol (acetaminophen) 10-325 tablets (Mallinckrodt)
Most hydrocodone formulations include a second analgesic, such as paracetamol (acetaminophen) or ibuprofen. Examples of hydrocodone combinations include Norco, Vicodin, Vicoprofen and Riboxen.[73]

Legal status[edit]
United States[edit]
The US government imposed tougher prescribing rules for hydrocodone in 2014, changing the drug from Schedule III to Schedule II.[74][75][76][77] In 2011, hydrocodone products were involved in around 100,000 abuse-related emergency department visits in the United States, more than double the number in 2004.[78]


References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Bonewit-West, Kathy; Hunt, Sue A.; Applegate, Edith (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN 9781455701506.

^ Jump up to: a b c d e f g h Jennifer A. Elliott; Howard S. Smith (19 April 2016). Handbook of Acute Pain Management. CRC Press. pp. 79–. ISBN 978-1-4665-9635-1.

^ Jump up to: a b c Gary S. Firestein; Ralph Budd; Sherine E. Gabriel; Iain B. McInnes; James R. O'Dell (21 June 2016). Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. pp. 1081–. ISBN 978-0-323-41494-4.

^ Jump up to: a b c d Bruce A. Chabner; Dan L. Longo (8 November 2010). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 700–. ISBN 978-1-60547-431-1.

^ Jump up to: a b c d e f g Shufeng Zhou (6 April 2016). Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism. CRC Press. pp. 164–. ISBN 978-1-4665-9788-4.

^ Jump up to: a b c Mellar P. Davis; Paul Glare; Janet Hardy (2005). Opioids in Cancer Pain. Oxford University Press. pp. 59–68. ISBN 978-0-19-852943-9.

^ Jump up to: a b Martin H. Bluth (16 November 2016). Toxicology and Drug Testing, An Issue of Clinics in Laboratory Medicine, E-Book. Elsevier Health Sciences. pp. 85–. ISBN 978-0-323-47795-6.

^ Jump up to: a b Howard S. Smith (21 February 2013). Opioid Therapy in the 21st Century. OUP USA. pp. 68–. ISBN 978-0-19-984497-5.

^ Jump up to: a b c d e f g h i j "Hydrocodone Bitartrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 April 2019.

^ Mallinckrodt (10 March 2021). "HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet (label)". National Institutes of Health DailyMed. Retrieved 6 November 2021.{{cite web}}:  CS1 maint: url-status (link)

^ Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J. (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. p. 692. ISBN 9781608317080.

^ "Hydrocodone: MedlinePlus Drug Information". medlineplus.gov. Retrieved 15 April 2019.

^ "Hydrocodone Use During Pregnancy". Drugs.com. Retrieved 15 April 2019.

^ "Opioid Dose Calculator". Agency Medical Directors' Group. Retrieved 15 April 2019.

^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 526. ISBN 9783527607495.

^ "Making Some Painkillers Harder to Get". The New York Times. 21 February 2013. Archived from the original on 3 January 2022. Retrieved 15 April 2019.

^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

^ "Hydrocodone Bitartrate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

^ Stoker, H. Stephen (2012). General, Organic, and Biological Chemistry. Cengage Learning. p. 567. ISBN 9781133711285.

^ Vardanyan, Ruben; Hruby, Victor (10 March 2006). Synthesis of Essential Drugs. Elsevier. ISBN 978-0-08-046212-7.

^ Narcotic Drugs 2020, Estimated World Requirements for 2021, Statistics for 2019 (PDF). International Narcotics Control Board. 2020. p. 37. ISBN 978-92-1-148355-0. Thebaine itself is not used in therapy, but it is an important starting material for the manufacture of a number of opioids, mainly codeine, dihydrocodeine, etorphine, hydrocodone, oxycodone and oxymorphone...

^ Galanie, Stephanie; Thodey, Kate; Trenchard, Isis J.; Filsinger Interrante, Maria; Smolke, Christina D. (4 September 2015). "Complete biosynthesis of opioids in yeast". Science. 349 (6252): 1095–1100. doi:10.1126/science.aac9373. ISSN 0036-8075. PMC 4924617. PMID 26272907.

^ Thodey, Kate; Galanie, Stephanie; Smolke, Christina D. (October 2014). "A microbial biomanufacturing platform for natural and semisynthetic opioids". Nature Chemical Biology. 10 (10): 837–844. doi:10.1038/nchembio.1613. ISSN 1552-4469. PMC 4167936. PMID 25151135.

^ Nakagawa, Akira; Matsumura, Eitaro; Koyanagi, Takashi; Katayama, Takane; Kawano, Noriaki; Yoshimatsu, Kayo; Yamamoto, Kenji; Kumagai, Hidehiko; Sato, Fumihiko; Minami, Hiromichi (5 February 2016). "Total biosynthesis of opiates by stepwise fermentation using engineered Escherichia coli". Nature Communications. 7 (1): 10390. doi:10.1038/ncomms10390. ISSN 2041-1723. PMC 4748248. PMID 26847395.

^ Zacny JP, Gutierrez S (April 2009). "Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers". Drug Alcohol Depend. 101 (1–2): 107–14. doi:10.1016/j.drugalcdep.2008.11.013. PMID 19118954.

^ Marco CA, Plewa MC, Buderer N, Black C, Roberts A (April 2005). "Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial". Acad Emerg Med. 12 (4): 282–8. doi:10.1197/j.aem.2004.12.005. PMID 15805317.

^ Jump up to: a b c Vallejo R, Barkin RL, Wang VC (2011). "Pharmacology of opioids in the treatment of chronic pain syndromes". Pain Physician. 14 (4): E343–60. doi:10.36076/ppj.2011/14/E343. PMID 21785485.

^ "Opioid (Narcotic Analgesics and Acetaminophen Systemic )". Retrieved 22 March 2014.

^ Mary Lynn McPherson (24 August 2009). Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. ASHP. pp. 187–188. ISBN 978-1-58528-297-5.

^ Jan Odom-Forren; Cecil Drain (11 February 2008). PeriAnesthesia Nursing: A Critical Care Approach. Elsevier Health Sciences. pp. 751–. ISBN 978-1-4377-2610-7.

^ Linda Skidmore-Roth (27 June 2013). Mosby's Drug Guide for Nursing Students, with 2014 Update. Elsevier Health Sciences. pp. 524–. ISBN 978-0-323-22268-6.

^ Vadivelu, Nalini; Schermer, Erika; Kodumudi, Gopal; Berger, Jack M. (2016). "The Clinical Applications of Extended-Release Abuse-Deterrent Opioids". CNS Drugs. 30 (7): 637–646. doi:10.1007/s40263-016-0357-0. ISSN 1172-7047. PMID 27290716. S2CID 26878027.

^ Jump up to: a b MedlinePlus; Drug Information: Hydrocodone. Last Revised—1 October 2008. Retrieved on 20 April 2013.

^ Friedman RA, House JW, Luxford WM, Gherini S, Mills D (March 2000). "Profound hearing loss associated with hydrocodone/acetaminophen abuse". Am J Otol. 21 (2): 188–91. doi:10.1016/S0196-0709(00)80007-1. PMID 10733182.

^ Ho T, Vrabec JT, Burton AW (May 2007). "Hydrocodone use and sensorineural hearing loss". Pain Physician. 10 (3): 467–72. PMID 17525781. Archived from the original on 23 July 2011.

^ Yorgason JG, Kalinec GM, Luxford WM, Warren FM, Kalinec F (June 2010). "Acetaminophen ototoxicity after acetaminophen/hydrocodone abuse: evidence from two parallel in vitro mouse models". Otolaryngol Head Neck Surg. 142 (6): 814–9, 819.e1–2. doi:10.1016/j.otohns.2010.01.010. PMID 20493351. S2CID 25083914.

^ Curhan SG, Eavey R, Shargorodsky J, Curhan GC (March 2010). "Analgesic use and the risk of hearing loss in men". Am. J. Med. 123 (3): 231–7. doi:10.1016/j.amjmed.2009.08.006. PMC 2831770. PMID 20193831.

^ "Neonatal abstinence syndrome: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 11 January 2022.

^ "Opioid Use and Opioid Use Disorder in Pregnancy". www.acog.org. Retrieved 11 January 2022.

^ Jump up to: a b "REPREXAIN (hydrocodone bitartrate, ibuprofen) tablet, film coated". dailymed.nlm.nih.gov. NIH. Retrieved 27 April 2013.

^ Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, Honein MA (April 2011). "Maternal treatment with opioid analgesics and risk for birth defects". Am. J. Obstet. Gynecol. 204 (4): 314.e1–11. doi:10.1016/j.ajog.2010.12.039. PMID 21345403.

^ Wightman R, Perrone J, Portelli I, Nelson L (December 2012). "Likeability and abuse liability of commonly prescribed opioids". J Med Toxicol. 8 (4): 335–40. doi:10.1007/s13181-012-0263-x. PMC 3550270. PMID 22992943.

^ Gnanadesigan N, Espinoza RT, Smith RL (June 2005). "The serotonin syndrome". N. Engl. J. Med. 352 (23): 2454–6, author reply 2454–6. doi:10.1056/NEJM200506093522320. PMID 15948273.

^ Jump up to: a b c Codd EE, Shank RP, Schupsky JJ, Raffa RB (September 1995). "Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception". J. Pharmacol. Exp. Ther. 274 (3): 1263–70. PMID 7562497.

^ Filizola M, Villar HO, Loew GH (January 2001). "Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors". Bioorg. Med. Chem. 9 (1): 69–76. doi:10.1016/S0968-0896(00)00223-6. PMID 11197347.

^ King (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 332–. ISBN 978-1-4496-1073-9.

^ David H. Chestnut; Cynthia A Wong; Lawrence C Tsen; Warwick D Ngan Kee; Yaakov Beilin; Jill Mhyre, eds. (28 February 2014). Chestnut's Obstetric Anesthesia: Principles and Practice E-Book. Elsevier Health Sciences. pp. 611–. ISBN 978-0-323-11374-8.

^ Adriana P. Tiziani (1 June 2013). Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 933–. ISBN 978-0-7295-8162-2.

^ Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (February 2004). "Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors". J. Pharmacol. Exp. Ther. 308 (2): 547–54. doi:10.1124/jpet.103.058602. PMID 14600248. S2CID 22492018.

^ Nicholas J Talley; Brad Frankum; David Currow (10 February 2015). Essentials of Internal Medicine 3e. Elsevier Health Sciences. pp. 491–. ISBN 978-0-7295-8081-6.

^ "Instructions for Mean Equivalent Daily Dose (MEDD)" (PDF). Archived from the original (PDF) on 27 July 2011. Retrieved 22 August 2010.

^ Mary C. Brucker; Tekoa L. King (8 September 2015). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 322–. ISBN 978-1-284-05748-5.

^ Steven B. Karch (9 October 2007). Pharmacokinetics and Pharmacodynamics of Abused Drugs. CRC Press. pp. 56–. ISBN 978-1-4200-5460-6.

^ Amitava Dasgupta; Jorge L. Sepulveda (22 January 2013). Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction. Newnes. pp. 239–. ISBN 978-0-12-415858-0.

^ Jump up to: a b Amitava Dasgupta; Loralie J. Langman (23 April 2012). Pharmacogenomics of Alcohol and Drugs of Abuse. CRC Press. pp. 175–. ISBN 978-1-4398-5611-6.

^ Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM (April 1997). "Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability". J. Pharmacol. Exp. Ther. 281 (1): 103–8. PMID 9103485.

^ Gardiner SJ, Begg EJ (September 2006). "Pharmacogenetics, drug-metabolizing enzymes, and clinical practice". Pharmacol. Rev. 58 (3): 521–90. doi:10.1124/pr.58.3.6. PMID 16968950. S2CID 25747320.

^ Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC (February 2012). "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype". Clin. Pharmacol. Ther. 91 (2): 321–6. doi:10.1038/clpt.2011.287. PMC 3289963. PMID 22205192.

^ Navani, D. M.; Yoburn, B. C. (2013). "In Vivo Activity of Norhydrocodone: An Active Metabolite of Hydrocodone". Journal of Pharmacology and Experimental Therapeutics. 347 (2): 497–505. doi:10.1124/jpet.113.207548. ISSN 1521-0103. PMID 23995596. S2CID 31072872.

^ Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G (October 2010). "Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions". Pediatrics. 126 (4): e986–9. doi:10.1542/peds.2009-1907. PMID 20837591. S2CID 42365304.

^ Vuilleumier PH, Stamer UM, Landau R (2012). "Pharmacogenomic considerations in opioid analgesia". Pharmgenomics Pers Med. 5: 73–87. doi:10.2147/PGPM.S23422. PMC 3513230. PMID 23226064.

^ Spiller HA (March 2003). "Postmortem oxycodone and hydrocodone blood concentrations". J. Forensic Sci. 48 (2): 429–31. doi:10.1520/JFS2002309. PMID 12665006.

^ Randall C. Baselt (2017). Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications. pp. 1050–1052. ISBN 978-0-692-77499-1.

^ Carroll, Robert (11 December 2008). "One Pot Conversion of Thebaine to Hydrocodone and Synthesis of Neopinone Ketal". Journal of Organic Chemistry. 74 (2): 747–752. doi:10.1021/jo802454v. PMID 19072148.

^ Sinatra, Raymond S. (6 December 2010). The Essence of Analgesia and Analgesics. Cambridge: Cambridge University Press. pp. 73, 81. ISBN 9780511841378.

^ Cruz, Silvia L. (27 October 2016). Neuroscience in the 21st Century. New York, NY: Springer. pp. 3626, 3657. ISBN 978-1-4939-3474-4.

^ Mannich, C.; Löwenheim, Helene (1920). "Ueber zwei neue Reduktionsprodukte des Kodeins". Archiv der Pharmazie. 258 (2–4): 295–316. doi:10.1002/ardp.19202580218. ISSN 0365-6233. S2CID 97513395.

^ "Drugs@FDA—Approval History: Hycodan". FDA. Retrieved 7 January 2006.

^ "FDA Docket No. 2007N-0353, Drug Products Containing Hydrocodone; Enforcement Action Dates". FDA. Retrieved 7 January 2006. See section I. B., DESI Review of Hydrocodone Products

^ PubChem. "Dihydromorphine". pubchem.ncbi.nlm.nih.gov. Retrieved 21 May 2021.

^ PubChem. "Dihydrocodeine". pubchem.ncbi.nlm.nih.gov. Retrieved 21 May 2021.

^ International Narcotics Control Board Report 2008. United Nations Pubns. 2009. p. 20. ISBN 978-9211482324.

^ "Hydrocodone Combination Products". MedlinePlus. The American Society of Health-System Pharmacists, Inc. Retrieved 14 July 2018.

^ McCarthy, Michael (2016). "Prescriptions for hydrocodone plummet after US tightens prescribing rules". BMJ. 352: i549. doi:10.1136/bmj.i549. ISSN 1756-1833. PMID 26819247. S2CID 45954090.

^ Jones, Christopher M.; Lurie, Peter G.; Throckmorton, Douglas C. (2016). "Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing". JAMA Internal Medicine. 176 (3): 399–402. doi:10.1001/jamainternmed.2015.7799. ISSN 2168-6106. PMID 26809459.

^ Chambers, Jan; Gleason, Rae M.; Kirsh, Kenneth L.; Twillman, Robert; Webster, Lynn; Berner, Jon; Fudin, Jeff; Passik, Steven D. (2016). "An Online Survey of Patients' Experiences Since the Rescheduling of Hydrocodone: The First 100 Days". Pain Medicine. 17 (9): 1686–1693. doi:10.1093/pm/pnv064. ISSN 1526-2375. PMID 26814291.

^ "Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". Federal Register. 22 August 2014. Retrieved 11 August 2017.

^ "Drug-Related Hospital Emergency Room Visits". National Institute on Drug Abuse. Retrieved 11 August 2017.


External links[edit]
"Hydrocodone". Drug Information Portal. U.S. National Library of Medicine.
"DEA Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". Federal Register. 6 October 2014.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAnalgesics (N02A, N02B)OpioidsOpiates/opium
Codeine#
+aspirin
+paracetamol
Morphine# (+naltrexone)
Opium
Laudanum
Paregoric
Semisynthetic
Acetyldihydrocodeine
Benzylmorphine
Buprenorphine (+naloxone)
Butorphanol
Desomorphine
Diamorphine (heroin)
Dihydrocodeine (+paracetamol)
Dihydromorphine
Etorphine
Ethylmorphine
Hydrocodone (+paracetamol, +ibuprofen, +aspirin)
Hydromorphinol
Hydromorphone
Levorphanol
Metopon
Nalbuphine
Nicocodeine
Nicodicodine
Nicomorphine
Oxycodone (+paracetamol, +aspirin, +ibuprofen, +naloxone, +naltrexone)
Oxymorphone
Papaveretum
Thebacon
Synthetic
Alfentanil
Alphaprodine
Anileridine
Bezitramide
Carfentanil
Dextromoramide
Dextropropoxyphene
Dezocine
Dimenoxadol
Dipipanone
Ethoheptazine
Fentanyl# (+fluanisone)
Ketobemidone
Lofentanil
Meptazinol
Methadone#
NFEPP
Norpipanone
Oliceridine
Pentazocine
Pethidine (meperidine)
Phenadoxone
Phenazocine
Phenoperidine
Piminodine
Piritramide
Proheptazine
Propiram
Remifentanil
Sufentanil
Tapentadol
Tilidine
Tramadol
Viminol
Paracetamol-type
Acetanilide‡
Bucetin‡
Butacetin‡
Paracetamol (acetaminophen)#
+aspirin/caffeine
+codeine
+hydrocodone
+metoclopramide
+oxycodone
+propyphenazone/caffeine
Parapropamol‡
Phenacetin‡
Propacetamol‡
NSAIDsPropionates
Benoxaprofen ‡
Fenoprofen
Flurbiprofen
Ibuprofen# (Dexibuprofen)
Ketoprofen (Dexketoprofen)
Loxoprofen
Naproxen
Oxaprozin
Suprofen
Tiaprofenic acid
Zaltoprofen
Oxicams
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam
Acetates
Acemetacin
Bromfenac
Diclofenac
Etodolac
Indometacin (Indometacin farnesil)
Ketorolac
Sulindac
Tolmetin
Zomepirac ‡
COX-2 inhibitors
Celecoxib (+tramadol)
Etoricoxib
Lumiracoxib ‡
Parecoxib
Rofecoxib ‡
Valdecoxib ‡
Fenamates
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Tolfenamic acid
Salicylates
Aspirin (acetylsalicylic acid)# (+paracetamol/caffeine)
Aloxiprin
Benorylate
Carbasalate calcium
Choline salicylate
Diflunisal
Dipyrocetyl
Ethenzamide
Guacetisal
Imidazole salicylate
Magnesium salicylate
Morpholine salicylate
Potassium salicylate
Salicin
Salicylamide
Salsalate
Sodium salicylate
Wintergreen (methyl salicylate)
Pyrazolones
Aminophenazone‡
Ampyrone
Metamizole (dipyrone)
Nifenazone
Phenazone
Propyphenazone (+paracetamol/caffeine)
Others
Benzydamine
Floctafenine
Glafenine
Nabumetone
Nimesulide
Proquazone
Cannabinoids
Cannabidiol
Cannabis
Nabilone
Nabiximols
Tetrahydrocannabinol (dronabinol)
Ion channelmodulatorsCalcium blockers
Alcohol (ethanol)
Gabapentin
Gabapentin enacarbil
Leconotide
Mirogabalin
Pregabalin
Ziconotide
Sodium blockers
Carbamazepine
Lacosamide
Local anesthetics (e.g., cocaine, lidocaine)
Mexiletine
Nefopam
Tricyclic antidepressants (e.g., amitriptyline#)
Nav1.7/1.8-selective: DSP-2230§
Funapide§
PF-05089771§
Potassium openers
Flupirtine‡
Myorelaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Mephenoxalone
Methocarbamol
Orphenadrine
Others
Analgecine
Analgesic adjuvant
Bedinvetmab
Camphor
Capsaicin
Clonidine
Frunevetmab
Ketamine
Menthol
Methoxyflurane
Phenazopyridine
Proglumide
Rimazolium
Tanezumab

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteCough and cold preparations (R05)Expectorants
Althea root
Antimony pentasulfide
Creosote
Guaiacolsulfonate
Guaifenesin (+ oxomemazine)
Ipecacuanha (Syrup of ipecac)
Levoverbenone
Potassium iodide
Senega
Tyloxapol
Ammonium Chloride
Mucolytics
Acetylcysteine#
Ambroxol
Bromhexine
Carbocisteine
Domiodol
Dornase alfa
Eprazinone
Erdosteine
Letosteine
Mannitol
Mesna
Neltenexine
Sobrerol
Stepronin
Cough suppressantsOpium alkaloids,opioids,and derivatives
Acetyldihydrocodeine
Benzylmorphine
Butorphanol
Codeine#
Dextromethorphan
Dihydrocodeine
Dimemorfan
Droxypropine
Ethylmorphine
Heroin
Hydrocodone
Hydromorphone
Isoaminile
Laudanum
Levomethadone
Levopropoxyphene
Methadone
Nicocodeine
Nicodicodeine
Normethadone
Noscapine
Pholcodine
Thebacon
Tipepidine
Other
Alloclamide
Benzonatate
Benproperine
Bibenzonium bromide
Butamirate
Clobutinol
Clofedanol
Cloperastine
Diphenhydramine
Dibunate
Dimethoxanate
Dropropizine
Fedrilate
Fominoben
Glaucine
Levodropropizine
Meprotixol
Moguisteine
Morclofone
Nepinalone
Oxolamine
Oxeladin
Pentoxyverine
Pipazetate
Prenoxdiazine
Piperidione
Zipeprol

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteOpioid receptor modulatorsMOR
Agonists (abridged; see here for a full list): 3-HO-PCP
7-Acetoxymitragynine
7-Hydroxymitragynine
ψ-Akuammigine
α-Chlornaltrexamine
α-Narcotine
Acetyldihydrocodeine
Acetylfentanyl
Acrylfentanyl
Adrenorphin (metorphamide)
AH-7921
Akuammicine
Akuammidine
Alfentanil
Anileridine
Apparicine
β-Endorphin
BAM-12P
BAM-18P
BAM-22P
Benzhydrocodone
Benzylmorphine
Bezitramide
Biphalin
BU08070
Buprenorphine
Butorphan
Butorphanol
Butyrfentanyl
BW373U86
Carfentanil
Casokefamide
Cebranopadol
Chloroxymorphamine
Codeine
DADLE
DAMGO (DAGO)
Dermorphin
Desmetramadol (desmethyltramadol)
Desomorphine
Dextromoramide
Dextropropoxyphene (propoxyphene)
Dezocine
Dimenoxadol
Dimethylaminopivalophenone
Eluxadoline
Diamorphine (heroin)
Dihydrocodeine
Dihydroetorphine
Dihydromorphine
Dinalbuphine sebacate
Diphenoxylate
Dipipanone
Dynorphin A
Embutramide
Endomorphin-1
Endomorphin-2
Eseroline
Ethylmorphine
Etorphine
Fentanyl
Fluorophen
Frakefamide
Furanylfentanyl
Hemorphin-4
Herkinorin
Hodgkinsine
Hydrocodone
Hydromorphinol
Hydromorphone
IBNtxA
Ketamine
Ketobemidone
Kratom
Laudanosine
Lefetamine
Leu-enkephalin
Levacetylmethadol
Levomethorphan
Levorphanol
Lexanopadol
Loperamide
Loxicodegol
LS-115509
Matrine
Meptazinol
Met-enkephalin (metenkefalin)
Methadone
Metkefamide
Metopon
Mitragynine
Mitragynine pseudoindoxyl
Morphiceptin
Morphine
Nalbuphine
NalBzOH
Nalmexone
Naltalimide
Neopine
NFEPP
Nicocodeine
Nicodicodine
Nicomorphine
NKTR-181
Norketamine
Nufenoxole
Octreotide
Oliceridine
OM-3-MNZ
Oripavine
Oxycodone
Oxymorphazone
Oxymorphonazine
Oxymorphone
Oxymorphone phenylhydrazone
OxyPNPH
Papaver somniferum (opium)
Pentazocine
Pericine
Pethidine (meperidine)
Phenazocine
Phencyclidine
Piminodine
Piritramide
PL-017
Prodine
Propiram
PZM21
Racemethorphan
Racemorphan
Remifentanil
Salsolinol
SC-17599
Sinomenine
Sufentanil
Tapentadol
Tetrahydropapaveroline
TH-030418
Thebaine
Thienorphine
Tianeptine
Tilidine
Tramadol
Trimebutine
TRIMU 5
TRV734
Tubotaiwine
U-47700
Valorphin
Viminol
Xorphanol
PAMs: BMS-986121
BMS-986122
Antagonists: (3S,4S)-Picenadol
2-(S)-N,N-(R)-Viminol
3CS-nalmefene
4-Caffeoyl-1,5-quinide
4′-Hydroxyflavanone
4',7-Dihydroxyflavone
6β-Naltrexol
6β-Naltrexol-d4
18-MC
α-Gliadin
β-Chlornaltrexamine
β-Funaltrexamine
Akuammine
Alvimopan
AM-251
Apigenin
AT-076
Axelopran
Bevenopran
Catechin
Catechin gallate
Clocinnamox
CTAP
CTOP
Cyclofoxy
Cyprodime
Diacetylnalorphine
Diprenorphine
ECG
EGC
Epicatechin
Eptazocine
Gemazocine
Ginsenoside R
Hyperoside
Ibogaine
JDTic
Levallorphan
Lobeline
LY-255582
LY-2196044
Methocinnamox
Methylnaltrexone
Methylsamidorphan chloride
Naldemedine
Nalmefene
Nalodeine (N-allylnorcodeine)
Nalorphine
Nalorphine dinicotinate
Naloxazone
Naloxegol
Naloxol
Naloxonazine
Naloxone
Naltrexazone
Naltrexonazine
Naltrexone
Naltrindole
Naringenin
Noribogaine
Oxilorphan
Pawhuskin A
Rimonabant
Quadazocine
Samidorphan
Taxifolin
Unknown/unsorted: Cannabidiol
Coronaridine
Cyproterone acetate
Dihydroakuuamine
Tabernanthine
Tetrahydrocannabinol
DOR
Agonists: 3CS-nalmefene
6'-GNTI
7-SIOM
ADL-5747 (PF-04856881)
ADL-5859
Alazocine (SKF-10047)
Amoxapine
AR-M100390 (ARM390)
AZD2327
β-Endorphin
BAM-18P
Biphalin
BU-48
Butorphan
Butorphanol
BW373U86
Casokefamide
Cebranopadol
Codeine
Cyclazocine
DADLE
Deltorphin A
Deltorphin I
Deltorphin II
Desmethylclozapine
Desmetramadol (desmethyltramadol)
Dezocine
Diamorphine (heroin)
Dihydroetorphine
Dihydromorphine
DPDPE
DPI-221
DPI-3290
DSLET
Ethylketazocine
Etorphine
Fentanyl
FIT
Fluorophen
Hemorphin-4
Hydrocodone
Hydromorphone
Ibogaine
Isomethadone
JNJ-20788560
KNT-127
Kratom
Laudanosine
Leu-enkephalin
Levomethorphan
Levorphanol
Lexanopadol
Lofentanil
Met-enkephalin (metenkefalin)
Metazocine
Metkefamide
Mitragynine
Mitragynine pseudoindoxyl
Morphine
N-Phenethyl-14-ethoxymetopon
Norbuprenorphine
NalBzOH
Oripavine
Oxycodone
Oxymorphone
Pethidine (meperidine)
Proglumide
Racemethorphan
Racemorphan
RWJ-394674
Samidorphan
SB-235863
SNC-80
SNC-162
TAN-67 (SB-205,607)
TH-030418
Thebaine
Thiobromadol (C-8813)
Tonazocine
Tramadol
TRV250
Xorphanol
Zenazocine
Antagonists: 4',7-Dihydroxyflavone
5'-NTII
6β-Naltrexol
6β-Naltrexol-d4
α-Santolol
β-Chlornaltrexamine
Apigenin
AT-076
Axelopran
Bevenopran
BNTX
Catechin
Catechin gallate
Clocinnamox
Diacetylnalorphine
Diprenorphine
ECG
EGC
Eluxadoline
Epicatechin
ICI-154129
ICI-174864
LY-255582
LY-2196044
Methylnaltrexone
Methylnaltrindole
N-Benzylnaltrindole
Nalmefene
Nalorphine
Naltrexone
Naltriben
Naltrindole
Naloxone
Naringenin
Noribogaine
Pawhuskin A
Quadazocine
SDM25N
SoRI-9409
Taxifolin
Thienorphine
Unknown/unsorted: 18-MC
Cannabidiol
Coronaridine
Cyproterone acetate
Tabernanthine
Tetrahydrocannabinol
KOR
Agonists: 3CS-nalmefene
6'-GNTI
8-CAC
18-MC
14-Methoxymetopon
β-Chlornaltrexamine
β-Funaltrexamine
Adrenorphin (metorphamide)
Akuuamicine
Alazocine (SKF-10047)
Allomatrine
Apadoline
Asimadoline
BAM-12P
BAM-18P
BAM-22P
Big dynorphin
Bremazocine
BRL-52537
Butorphan
Butorphanol
BW373U86
Cebranopadol
Ciprefadol
CR665
Cyclazocine
Cyclorphan
Cyprenorphine
Desmetramadol (desmethyltramadol)
Diamorphine (heroin)
Diacetylnalorphine
Difelikefalin
Dihydroetorphine
Dihydromorphine
Dinalbuphine sebacate
Diprenorphine
Dynorphin A
Dynorphin B (rimorphin)
Eluxadoline
Enadoline
Eptazocine
Erinacine E
Ethylketazocine
Etorphine
Fedotozine
Fentanyl
Gemazocine
GR-89696
GR-103545
Hemorphin-4
Herkinorin
HS665
Hydromorphone
HZ-2
Ibogaine
ICI-199,441
ICI-204,448
Ketamine
Ketazocine
Laudanosine
Leumorphin (dynorphin B-29)
Levallorphan
Levomethorphan
Levorphanol
Lexanopadol
Lofentanil
LPK-26
Lufuradom
Matrine
MB-1C-OH
Menthol
Metazocine
Metkefamide
Mianserin
Mirtazapine
Morphine
Moxazocine
MR-2034
N-MPPP
Nalbuphine
NalBzOH
Nalfurafine
Nalmefene
Nalodeine (N-allylnorcodeine)
Nalorphine
Naltriben
Niravoline
Norbuprenorphine
Norbuprenorphine-3-glucuronide
Noribogaine
Norketamine
Oripavine
Oxilorphan
Oxycodone
Pentazocine
Pethidine (meperidine)
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
RB-64
Salvinorin A (salvia)
Salvinorin B ethoxymethyl ether
Salvinorin B methoxymethyl ether
Samidorphan
Spiradoline (U-62,066)
TH-030418
Thienorphine
Tifluadom
Tricyclic antidepressants (e.g., amitriptyline, desipramine, imipramine, nortriptyline)
U-50488
U-54,494A
U-69,593
Xorphanol
Antagonists: 4′-Hydroxyflavanone
4',7-Dihydroxyflavone
5'-GNTI
6'-GNTI
6β-Naltrexol
6β-Naltrexol-d4
β-Chlornaltrexamine
Buprenorphine/samidorphan
Amentoflavone
ANTI
Apigenin
Arodyne
AT-076
Aticaprant
Axelopran
AZ-MTAB
Binaltorphimine
BU09059
Buprenorphine
Catechin
Catechin gallate
CERC-501 (LY-2456302)
Clocinnamox
Cyclofoxy
Dezocine
DIPPA
EGC
ECG
Epicatechin
Hyperoside
JDTic
LY-255582
LY-2196044
LY-2444296
LY-2459989
LY-2795050
MeJDTic
Methylnaltrexone
ML190
ML350
MR-2266
N-Fluoropropyl-JDTic
Naloxone
Naltrexone
Naltrindole
Naringenin
Norbinaltorphimine
Noribogaine
Pawhuskin A
PF-4455242
RB-64
Quadazocine
Taxifolin
UPHIT
Zyklophin
Unknown/unsorted: Akuammicine
Akuammine
Coronaridine
Cyproterone acetate
Dihydroakuuamine
Ibogamine
Tabernanthine
NOP
Agonists: (Arg14,Lys15)Nociceptin
((pF)Phe4)Nociceptin(1-13)NH2
(Phe1Ψ(CH2-NH)Gly2)Nociceptin(1-13)NH2
Ac-RYYRWK-NH2
Ac-RYYRIK-NH2
BU08070
Buprenorphine
Cebranopadol
Dihydroetorphine
Etorphine
JNJ-19385899
Levomethorphan
Levorphanol
Lexanopadol
MCOPPB
MT-7716
NNC 63-0532
Nociceptin (orphanin FQ)
Nociceptin (1-11)
Nociceptin (1-13)NH2
Norbuprenorphine
Racemethorphan
Racemorphan
Ro64-6198
Ro65-6570
SCH-221510
SCH-486757
SR-8993
SR-16435
Sunobinop (S-117957)
TH-030418
Antagonists: (Nphe1)Nociceptin(1-13)NH2
AT-076
BAN-ORL-24
BTRX-246040 (LY-2940094)
J-113,397
JTC-801
NalBzOH
Nociceptin (1-7)
Nocistatin
SB-612,111
SR-16430
Thienorphine
Trap-101
UFP-101
Unsorted
β-Casomorphins
Amidorphin
BAM-20P
Cytochrophin-4
Deprolorphin
Gliadorphin (gluteomorphin)
Gluten exorphins
Hemorphins
Kava constituents
MEAGL
MEAP
NEM
Neoendorphins
Nepetalactone (catnip)
Peptide B
Peptide E
Peptide F
Peptide I
Rubiscolins
Soymorphins
Others
Enkephalinase inhibitors: Amastatin
BL-2401
Candoxatril
D -Phenylalanine
Dexecadotril (retorphan)
Ecadotril (sinorphan)
Kelatorphan
Racecadotril (acetorphan)
RB-101
RB-120
RB-3007
Opiorphan
Selank
Semax
Spinorphin
Thiorphan
Tynorphin
Ubenimex (bestatin)
Propeptides: β-Lipotropin (proendorphin)
Prodynorphin
Proenkephalin
Pronociceptin
Proopiomelanocortin (POMC)
Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





